Redesigning Quality Reporting Lines Directly to Corporate Governance Boards
Redesigning quality reporting directly to corporate boards removes operational bias, enforces independent stop-work authority, and protects enterprise margin.
EU MDR Article 15
Meaning
European regulatory frameworks for medical devices demand that manufacturers designate a specific internal resource to ensure complete adherence to quality and safety standards. Under EU MDR Article 15, manufacturers must have at least one person responsible for regulatory compliance who possesses the requisite expertise in the field of medical devices. This individual must personally oversee that the conformity of the devices is properly checked, the technical documentation is kept up to date, and the post-market surveillance obligations are fulfilled.
This requirement applies to both European manufacturers and authorized representatives who act on behalf of non-European companies, ensuring a uniform level of quality control across all borders.
Technical Liability
The individual appointed under this regulation bears direct personal responsibility for the safety and compliance of the products placed on the market. If a manufacturer releases a medical device that does not conform to the approved design, the person designated under EU MDR Article 15 can be held legally liable for the failure. This level of accountability requires the designated person to have the authority to block the shipment of non-compliant batches.
Organizational Structure
Implementing this requirement forces companies to adjust their reporting lines to protect the designated individual from commercial pressures. The compliance officer must be placed in a position where they can act independently and cannot be penalized for doing their job. This separation prevents the production department from rushing products to market before all quality checks are complete.
Market Access
Operating a medical device manufacturing facility without a qualified person responsible for regulatory compliance leads to an immediate loss of the CE mark and the halt of sales in Europe. For startups transitioning from prototype development to clinical trials and full market release, securing this resource is a critical milestone. The appointment is audited during every annual review by notified bodies.